Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment

Zhang, Yuting; Lü, Guoqiang; Sun, Menghong; Lü, Xin

doi:10.20892/j.issn.2095-3941.2019.0372

Cited by 59 publications

(43 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the pro-and anti-tumorigenic role of TAN2 and TAN1, respectively, can be confirmed in humans, the potential switching of TAN2 into TAN1 could become a worthwhile strategy in cancer therapy. Alternatively, if TAN2 cells turn out to be PMN-MDSCs, strategies to neutralize the immunosuppressive functions of PMN-MDSCs could apply (for review [158]). Only the identification of markers could favor one scenario over another, namely if TAN1 are in fact bona fide neutrophils, and TAN2 related to PMN-MDSCs, or TAN1 and TAN2, correspond to two different phenotypes of neutrophils.…”

Section: Discussionmentioning

confidence: 99%

“…Alternatively, an emerging and promising concept for cancer therapy based on the neutrophil properties, would entail the delivery of therapeutics at the tumor site by viable neutrophils or neutrophil membranederived nanovesicles, since the infiltration of these cells is associated with tumorigenesis. Such technologies are in their early stages and will have to await further data to prove their therapeutic potential [158,160,161].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Tolle

Umansky

Utikal

et al. 2021

IJMS

View full text Add to dashboard Cite

Neutrophils—once considered as simple killers of pathogens and unexciting for cancer research—are now acknowledged for their role in the process of tumorigenesis. Neutrophils are recruited to the tumor microenvironment where they turn into tumor-associated neutrophils (TANs), and are able to initiate and promote tumor progression and metastasis. Conversely, anti-tumorigenic properties of neutrophils have been documented, highlighting the versatile nature and high pleiotropic plasticity of these polymorphonuclear leukocytes (PMN-L). Here, we dissect the ambivalent roles of TANs in cancer and focus on selected functional aspects that could be therapeutic targets. Indeed, the critical point of targeting TAN functions lies in the fact that an immunosuppressive state could be induced, resulting in unwanted side effects. A deeper knowledge of the mechanisms linked to diverse TAN functions in different cancer types is necessary to define appropriate therapeutic strategies that are able to induce and maintain an anti-tumor microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Tolle

Umansky

Utikal

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Neutrophil polarization may affect their role in the tumor microenvironment. Similar to the classification of M1/M2 macrophages, TANs are sorted into antitumorigenic N1 phenotype and pro-tumorigenic N2 phenotype on the basis of their functional differences (Zhang Y. et al, 2020). TGF-β and type I IFN-γ were suggested to play essential roles in the polarization of TANs switching from N1 to N2 (Fridlender et al, 2009;Pylaeva et al, 2016).…”

Section: Immune Inflammatory Cells and Drug Resistancementioning

confidence: 99%

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Zhou

Yang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug resistance. However, recent evidence showed that tumor microenvironment (TME) is essential for regulating immune escape, drug resistance, progression and metastasis of malignant cells. Reciprocal interactions between cancer cells and non-malignant cells within this milieu often reshape the TME and promote drug resistance. Therefore, advanced knowledge about these sophisticated interactions is significant for the design of effective therapeutic approaches. In this review, we highlight cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), T-regulatory lymphocytes (Tregs), mesenchymal stem cells (MSCs), cancer-associated adipocytes (CAAs), and tumor endothelial cells (TECs) existing in TME, as well as their multiple cross-talk with tumor cells, which eventually endows tumor cells with therapeutic resistance.

show abstract

“…NEs, the most abundant immune cells, are the first to respond to infection or tumors and are closely related to tumor progression; thus, they are potentially useful as excellent carriers of antitumor drugs (Han et al, 2018 ; Zhang et al, 2020 ). Glioblastoma grows rapidly and has a high fatality rate, increasing the difficulty of complete surgical resection, and the BBB and BBTB also prevent common chemotherapy drugs from easily passing through and reaching the tumor site, resulting in a high tumor recurrence rate.…”

Section: Cell Membrane-coated Nanoparticlesmentioning

confidence: 99%

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Zhao

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Nanotechnology provides synthetic carriers for cancer drug delivery that protect cargos from degradation, control drug release and increase local accumulation at tumors. However, these non-natural vehicles display poor tumor targeting and potential toxicity and are eliminated by the immune system. Recently, biomimetic nanocarriers have been widely developed based on the concept of 'mimicking nature.' Among them, cell-derived biomimetic vehicles have become the focus of bionics research because of their multiple natural functions, such as low immunogenicity, long circulation time and targeting ability. Cell membrane-coated carriers and extracellular vesicles are two widely used cell-based biomimetic materials. Here, this review summarizes the latest progress in the application of these two biomimetic carriers in targeted cancer therapy. Their properties and performance are compared, and their future challenges and development prospects are discussed.

show abstract

Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment

Cited by 59 publications

References 100 publications

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles

Contact Info

Product

Resources

About